211 related articles for article (PubMed ID: 28530531)
1. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
2. Bacterial Growth Inhibition Screen (BGIS) identifies a loss-of-function mutant of the DEK oncogene, indicating DNA modulating activities of DEK in chromatin.
Guo H; Prell M; Königs H; Xu N; Waldmann T; Hermans-Sachweh B; Ferrando-May E; Lüscher B; Kappes F
FEBS Lett; 2021 May; 595(10):1438-1453. PubMed ID: 33686684
[TBL] [Abstract][Full Text] [Related]
3. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
4. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
5. DEK oncogene is overexpressed during melanoma progression.
Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
[TBL] [Abstract][Full Text] [Related]
6. The unique DEK oncoprotein in women's health: A potential novel biomarker.
de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
[TBL] [Abstract][Full Text] [Related]
7. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.
Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
[TBL] [Abstract][Full Text] [Related]
8. Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling.
Capitano ML; Mor-Vaknin N; Saha AK; Cooper S; Legendre M; Guo H; Contreras-Galindo R; Kappes F; Sartor MA; Lee CT; Huang X; Markovitz DM; Broxmeyer HE
J Clin Invest; 2019 May; 129(6):2555-2570. PubMed ID: 31107242
[TBL] [Abstract][Full Text] [Related]
9. Control of tumorigenesis and chemoresistance by the DEK oncogene.
Riveiro-Falkenbach E; Soengas MS
Clin Cancer Res; 2010 Jun; 16(11):2932-8. PubMed ID: 20501624
[TBL] [Abstract][Full Text] [Related]
10. DEK over-expression promotes mitotic defects and micronucleus formation.
Matrka MC; Hennigan RF; Kappes F; DeLay ML; Lambert PF; Aronow BJ; Wells SI
Cell Cycle; 2015; 14(24):3939-53. PubMed ID: 25945971
[TBL] [Abstract][Full Text] [Related]
11. The distribution of the DEK protein in mammalian chromatin.
Hu HG; Scholten I; Gruss C; Knippers R
Biochem Biophys Res Commun; 2007 Jul; 358(4):1008-14. PubMed ID: 17524367
[TBL] [Abstract][Full Text] [Related]
12. The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.
Sandén C; Järvstråt L; Lennartsson A; Brattås PL; Nilsson B; Gullberg U
Mol Cancer; 2014 Sep; 13():215. PubMed ID: 25216995
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-138 promotes neuroblastoma SH-SY5Y cell apoptosis by directly targeting DEK in Alzheimer's disease cell model.
Miao J; Jing J; Shao Y; Sun H
BMC Neurosci; 2020 Jul; 21(1):33. PubMed ID: 32736520
[TBL] [Abstract][Full Text] [Related]
14. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.
Kappes F; Fahrer J; Khodadoust MS; Tabbert A; Strasser C; Mor-Vaknin N; Moreno-Villanueva M; Bürkle A; Markovitz DM; Ferrando-May E
Mol Cell Biol; 2008 May; 28(10):3245-57. PubMed ID: 18332104
[TBL] [Abstract][Full Text] [Related]
15. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
16. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
17. Imaging-based study demonstrates how the DEK nanoscale distribution differentially correlates with epigenetic marks in a breast cancer model.
Pierzynska-Mach A; Cainero I; Oneto M; Ferrando-May E; Lanzanò L; Diaspro A
Sci Rep; 2023 Aug; 13(1):12749. PubMed ID: 37550322
[TBL] [Abstract][Full Text] [Related]
18. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI
Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316
[TBL] [Abstract][Full Text] [Related]
19. The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress.
Deutzmann A; Ganz M; Schönenberger F; Vervoorts J; Kappes F; Ferrando-May E
Oncogene; 2015 Aug; 34(32):4270-7. PubMed ID: 25347734
[TBL] [Abstract][Full Text] [Related]
20. DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.
Mor-Vaknin N; Saha A; Legendre M; Carmona-Rivera C; Amin MA; Rabquer BJ; Gonzales-Hernandez MJ; Jorns J; Mohan S; Yalavarthi S; Pai DA; Angevine K; Almburg SJ; Knight JS; Adams BS; Koch AE; Fox DA; Engelke DR; Kaplan MJ; Markovitz DM
Nat Commun; 2017 Feb; 8():14252. PubMed ID: 28165452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
